Navigation Links
Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
Date:2/5/2008

RICHMOND, Va., Feb. 5 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM) CEO Geoffrey Allan issued the following statement today following the White House FY09 Budget and Food and Drug Administration statements on developing an approval pathway for follow-on biologics:

"Insmed is very pleased to see that the White House recognizes the importance of establishing a follow-on biologics approval pathway to deliver safe and more affordable medicines to Americans.

"We are also pleased by news of the Food and Drug Administration's preparation of a proposal to assist the Congress in moving forward with legislation to establish an approval pathway for follow-on biologics.

"We hope that the attention this important issue has received from both the White House and FDA will move Congress to adopt follow-on biologics legislation so patients can receive safe and affordable access to generic versions of these life-saving biotech drugs."

About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. Insmed has a state-of-the- art, FDA-approved biologic commercial manufacturing facility in Boulder, Colorado and a Corporate office in Richmond, Virginia. For more information, please visit http://www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results
'/>"/>

SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
2. Insmed to Appeal Delisting Notification From Nasdaq
3. Insmed Awarded $2.1 Million by Muscular Dystrophy Association
4. Insmed Appoints Dennis M. Lanfear to Board Of Directors
5. Baxter Issues Urgent Nationwide Voluntary Recall of Heparin 1,000 Units/mL 10 and 30mL Multi-Dose Vials
6. FDA Issues Approvable Letter for LUVOX(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD)
7. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
8. CCPM Issues Statement on FDAs GIVE Initiative
9. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
10. CalbaTech Issues Update; Beginning Training for Adult Stem Cell Collections in Atlanta
11. HHS Issues First Department-Wide Report on Personalized Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)...  Caris Life Sciences® today announced the presentation ... identified biomarker changes, including key driver mutations, in ... in response to therapy as the disease progresses. ... of a larger study analyzing 1,245 glioma samples ... data utilizing Caris Molecular Intelligence®, the company,s panomic ...
(Date:5/29/2015)... , May 29, 2015 BerGenBio ... today announces that an abstract on the latest data ... of the Axl receptor tyrosine kinase, and BGB10C9, an ... has been published in conjunction with the 2015 American ... Chicago , May 29 - June 2, ...
(Date:5/29/2015)... , May 29, 2015 ... p ersonalized   treatments enter arena, says   ... Despite generic erosion facing several of the leading ... (budesonide/formoterol fumarate) and Xolair (omalizumab), the global market for ... the end of the decade.   New ...
(Date:5/29/2015)... 2015 When a leading manufacturer ... request to design an industrial oven ... medications being produced using a 3D-printing process, Gruenberg ... robotic gantry, heat-saving windows, and internal actuators and ... 3D-printed pills to exact specifications. , To ensure ...
Breaking Biology Technology:Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 2Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 3Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 4BGB324 and BGB10C9 Show Promise in Models of Pancreatic Cancer 2BGB324 and BGB10C9 Show Promise in Models of Pancreatic Cancer 3Personalized Treatment for Severe Asthma to Drive Market Growth Despite Patent Expirations 2Personalized Treatment for Severe Asthma to Drive Market Growth Despite Patent Expirations 3New industrial oven with “pill pushing” robotic gantry precisely removes excess moisture from 3D-printed pharmaceuticals 2
... Inc. (NYSE Alternext US: DDD) today reported financial results ... 2008. The Company will host a live conference ... Daylight Time)."Last year was an important period for SCOLR ... M.B.A. "Utilizing our unique CDT(R) platforms, we made significant ...
... Radiotherapy Department in State of Qatar to Introduce ... One of the leading cancer centers in ... devices from Varian Medical Systems (NYSE: ... and precise treatments. Al Amal Hospital in Doha, ...
... Neogen Corporation (Nasdaq: NEOG ) announces ... Results WebcastWhen: Thursday, March 19, 2009 @ ... Live over the Internet -- Simply log on ... Contact: Terry Maynard of Neogen Corporation, +1-800-234-5333.If ...
Cached Biology Technology:SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 2SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 3SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 4SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 5SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 6SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 7SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 8Leading Middle East Cancer Hospital Acquires Advanced Radiotherapy Capability from Varian Medical Systems 2Leading Middle East Cancer Hospital Acquires Advanced Radiotherapy Capability from Varian Medical Systems 3
(Date:5/6/2015)... , May 6, 2015 LifeBEAM, a ... established helmet producer, announced today that they will expand ... the world,s first bio-sensing cycling helmet and the first ... in two new colors in order to give cyclists ... product. In addition, LifeBEAM and Lazer announced their plan ...
(Date:4/21/2015)... April 21, 2015 High ... policies are boosting access control systems market in ... to a recently published report by TechSci Research " ... the access control systems market in Saudi ... by 2020.The access control systems market in the Kingdom ...
(Date:4/14/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... York Design Awards under the category  ,Product Design – ... Awards are part of a global multi-disciplinary awards program. ... the marketplace, industry and judging panel. Winners will be ...
Breaking Biology News(10 mins):LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... toxic protein particles severely disrupt neurotransmission and inhibit delivery ... by Marine Biological Laboratory (MBL) researchers have found. ... has long been known to accumulate and form plaques ... small particles that haven,t aggregated into plaquesthese are increasingly ...
... Mutations in a gene may cause poor lung development in ... obstructive pulmonary disease (COPD) later in life, say researchers at ... the German Research Center for Environmental Health. Their study, published ... the gene and its variants in both mouse lungs and ...
... A University of Florida scientist whose interest in embryonic ... building blocks that shape appendages ranging from feet to ... Career Scientist today (Thursday, March 26), a distinction given ... Martin Cohn, a developmental biologist and a member of ...
Cached Biology News:Tiny but toxic: MBL researchers discover a mechanism of neurodegeneration in Alzheimer's disease 2Changes in gene may stunt lung development in children 2UF scientist tapped by Howard Hughes Medical Institute to pursue 'best ideas' 2UF scientist tapped by Howard Hughes Medical Institute to pursue 'best ideas' 3
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
... Experion Pro260 analysis kit for 10 chips ... perform protein analysis with the Experion automated ... microfluidic chips, 3 x 520 microliters Pro260 ... Pro260 ladder (10-260 kD), 400 microliters Pro260 ...
... expertise that made the original Gene Pulser apparatus ... available has been applied in the Gene Pulser ... modular design of the Gene Pulser II system ... that has the widest range of settings to ...
Experion Pro260 chips are the microfluidic chips used to perform protein analysis with the Experion automated electrophoresis system. Each chip has the capacity to run 10 protein samples. Supplied as...
Biology Products: